(Q39270928)

10 September 2017

Neighbor communities in drug combination networks characterize synergistic effect (English)

1 reference

10 September 2017

Jun Zou

1

1 reference

10 September 2017

Pan Ji

2

1 reference

10 September 2017

Ying-Lan Zhao

3

1 reference

10 September 2017

Lin-Li Li

4

1 reference

10 September 2017

Yu-Quan Wei

5

1 reference

10 September 2017

Yu-Zong Chen

6

1 reference

10 September 2017

Sheng-Yong Yang

7

1 reference

10 September 2017

1 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

8

1 reference

10 September 2017

12

1 reference

10 September 2017

3185-3196

1 reference

Systems pathology--taking molecular pathology into a new dimension

10 September 2017

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Chemogenomic profiling predicts antifungal synergies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Protein dynamics in drug combinations: a linear superposition of individual-drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Prediction of drug combinations by integrating molecular and pharmacological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Models from experiments: combinatorial drug perturbations of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Finding multiple target optimal intervention in disease-related molecular network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Physicochemical modelling of cell signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Interactome networks and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Network medicine: a network-based approach to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Relating protein adduction to gene expression changes: a systems approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Mapping the genome of Plasmodium falciparum on the drug-like chemical space reveals novel anti-malarial targets and potential drug leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Network target for screening synergistic drug combinations with application to traditional Chinese medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Prediction of drug-target interactions and drug repositioning via network-based inference

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

ChEMBL: a large-scale bioactivity database for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

The BioGRID Interaction Database: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

The IntAct molecular interaction database in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Human Protein Reference Database--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

MINT, the molecular interaction database: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

The Protein Identifier Cross-Referencing (PICR) service: reconciling protein identifiers across multiple source databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Integrating physical and genetic maps: from genomes to interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Systematic exploration of synergistic drug pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Systems biology and combination therapy in the quest for clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

KEGG for integration and interpretation of large-scale molecular data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Parsimonious discovery of synergistic drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

GOSim--an R-package for computation of information theoretic GO similarities between terms and gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Evaluation of GO-based functional similarity measures using S. cerevisiae protein interaction and expression profile data

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Enrichment and aggregation of topological motifs are independent organizational principles of integrated interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

Translating cancer research into targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25267H

21 January 2018

Identifiers

DOI

10.1039/C2MB25267H

1 reference

release_6oa4oejgsraovcqof33hncaguq

10 September 2017

0 references

1 reference